2-Chloro-4-[(4-chloro-1H-pyrazol-1-yl)methyl]pyridine

Catalog No. :
ACXITA524
CAS No. :
1248056-07-6
Molecular Formula :
C9H7Cl2N3
Molecular Weight :
228.08

IUPAC Name:2-chloro-4-((4-chloro-1H-pyrazol-1-yl)methyl)pyridine

2-Chloro-4-[(4-chloro-1H-pyrazol-1-yl)methyl]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$303.00Login to see priceInquiryInquiry
100mg98%$443.00Login to see priceInquiryInquiry
250mg98%$624.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-Chloro-4-[(4-chloro-1H-pyrazol-1-yl)methyl]pyridine
IUPAC Name2-chloro-4-((4-chloro-1H-pyrazol-1-yl)methyl)pyridine
MDL No.MFCD16765174
Molecular FormulaC9H7Cl2N3
Molecular Weight228.08
SMILESClC1=CN(CC2=CC(Cl)=NC=C2)N=C1
InChI KeyOWNOPWZQDVXQKJ-UHFFFAOYSA-N
SynonymPyridine, 2-chloro-4-[(4-chloro-1H-pyrazol-1-yl)methyl]-;2-chloro-4-[(4-chloro-1H-pyrazol-1-yl)methyl]pyridine
CAS No.1248056-07-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACXITA524 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCHDR479 route compound structure diagram
    ACCHDR47932938-48-0 In Stock
  2. Plus
  3. ACFXNO065 route compound structure diagram
    ACFXNO06515878-00-9 In Stock
  4. Then
  5. ACXITA524 route product structure diagram
    ACXITA5241248056-07-6
Inquiry

2. ACXITA524 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFCMP467 route compound structure diagram
    ACFCMP467117934-37-9 In Stock
  2. Plus
  3. ACFXNO065 route compound structure diagram
    ACFXNO06515878-00-9 In Stock
  4. Then
  5. ACXITA524 route product structure diagram
    ACXITA5241248056-07-6
Inquiry

Comments (0)